

March 7, 2018

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

Please find attached press release issued by the Company titled:

Thanks and Regards





Press Release

Marc 7, 2018

Strides Shasun Limited
(Former Strides Pharmacol Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun Limited today announced that it will launch **Ranitidine Tablets USP, 75 mg (OTC)** for the US markets. The new launch further strengthens Strides' Ranitidine portfolio that now includes **Ranitidine Tablets** in the Rx space and **Ranitidine Tablets** in the OTC space. Strides is already a key player with 32% share of the US Rx market for Ranitidine. According to IRI data, the US OTC market for , which is the generic form of the popular brand , is approximately USD 200 Million.

This is the second product approval from company's 50:50 JV with Vivimed Labs. The product will be backward integrated and will be manufactured at the JV's Oral dosage facility in Chennai. Strides will have exclusive marketing rights for the product in the US. The product will be launched immediately.

The company has 82 cumulative ANDA filings with USFDA (including it's JV with Vivimed) of which 51 ANDAs have been approved as of date and 31 are pending approval.

Ranitidine belongs to a class of drugs known as H2 histamine blockers. It is used to treat peptic ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion.



Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com

<p><u>Strides:</u></p> <p>Shashank Sinha, Managing Director +91 80 6784 0335</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: investors@stridesshasun.com</p>	<p><u>PR Consultancy:</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com</p> <p>K Priya: +91 9535425418 priya@fortunapr.com</p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

